-- 周二,主要生物燃料原料期货价格涨跌互现,此前有报道称,尽管美国封锁了停靠伊朗港口的船只,但美伊两国可能恢复和平谈判,受此消息影响,原油价格下跌。 芝加哥期货交易所(CBOT)5月大豆油期货合约早盘下跌0.35%,至每磅66.27美分;而5月大豆期货合约早盘上涨0.34%,至每蒲式耳11.66美元。 由于美元走软,美国出口产品更具吸引力,大豆价格与原油价格走势出现分化。 然而,价格报告机构MySteel表示,由于化肥成本上涨,农民将种植面积从玉米转向大豆,预计美国大豆产量将会增加,这限制了价格涨幅。 美国农业部周一报告称,截至4月12日,大豆种植进度已达6%,高于去年同期的2%。 该机构还报告称,截至4月9日当周,美国对814,562公吨大豆出口进行了检验,高于前一周的804,892公吨。这使得本销售年度的出口检验总量达到3150万吨,而上一销售年度为4210万吨。 在亚洲,由于豆油价格走低,且出口下降打击了市场情绪,马来西亚棕榈油价格周二下跌2%。 马来西亚衍生品交易所5月和6月原棕榈油合约分别跌至每公吨4,420马来西亚林吉特(1,117.01美元)和4,466林吉特,创下3月中旬以来的最低水平。 初步估计显示,4月前10天马来西亚棕榈油出货量环比下降30.7%至38.9%,这给价格带来了压力。 据印度溶剂萃取协会(Solvent Extractors' Association of India)的数据显示,印度3月份棕榈油进口量降至三个月以来的最低点689,462公吨,低于2月份的847,689公吨。大豆油进口量也环比下降4%,至287,220公吨。 据《The Edge》和Trading Economics援引分析师的话称,由于价格居高不下,印度买家下周可能会继续谨慎增购,但最终可能会增加进口以备季节性需求旺盛时之需。 随着印尼和泰国生物燃料掺混比例的提高,马来西亚出口竞争力预计将有所提升,因为两国的供应量将会减少。 据马来西亚国家通讯社(Bernama)援引投资银行的消息报道,由于持续的中东冲突造成的供应不确定性,尽管价格上涨,买家仍在加速囤货,这也将继续推动马来西亚出口。 据肯纳格投资银行报道,这种消费行为在3月份有所体现。尽管2月底地缘政治冲突爆发后价格飙升,马来西亚的出口量仍比上月增长了40.7%。 据大众投资银行预测,由于出口依然强劲,未来两个月马来西亚的库存量可能降至约200万吨。 据《新海峡时报》援引联昌证券的预测,如果需求持续旺盛且产量下降,4月份国内库存量将从3月份的230万吨降至220万吨。 化肥供应中断和厄尔尼诺现象对马来西亚的棕榈油产量构成下行风险。 周一,纽约商品交易所(NYMEX)5月份交割的乙醇期货价格小幅上涨0.13%,至每加仑约1.94美元。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.